Table 6.
Representative clinical trials of the delivery platforms with mRNA-LNPs against various cancers.
| Name of vaccine / Sponsor | Disease | Delivery platform | Encoding sequence | ICI | ClinicalTrials.gov.identifier / Phase |
|---|---|---|---|---|---|
| FixVac (BNT111) / BioNTech RNA Pharmaceuticals GmbH | Melanoma | Lipo-MERIT | NY-ESO-1 Tyrosinase MAGE-A3 TPTE |
Vemurafenib Dabrafenib Nivolumab Pembrolizumab Cemiplimab |
NCT02410733 / 1 NCT04526899 / 2 |
| BNT114 / BioNTech SE | TNBC | TNBC-MERIT | TAA | N.A. | NCT02316457 / 1 |
| RO7198457 / BioNTech SE, Genentech | - NSCLC - Melanoma - TNBC - Colon cancer - Bladder cancer |
Lipo-MERIT | Neoantigen | Atezolizumab |
NCT03313778 / 1a, 1b NCT03897881 / 2 |
| mRNA-4157 / Moderna Therapeutics | - NSCLC - Melanoma - Bladder urothelial cancer - HPV-HNSCC |
mRNA-LNP | Neoantigen | Pembrolizumab |
NCT03313778 / 1 NCT03897881 / 2 |
| mRNA-4650 / Moderna Therapeutics | Metastatic melanoma | mRNA-LNP | Neoantigen | N.A. | NCT03480152 / 1 |
| mRNA-2416 / Moderna Therapeutics | - Solid tumor - Lymphoma |
mRNA-LNP | OX40L | Durvalumab | NCT03323398 / 1 |
| mRNA-2752 / Moderna Therapeutics | - Solid tumor - Lymphoma |
mRNA-LNP | OX40L, IL-23, IL-36y | Durvalumab | NCT03739931 / 1 |
| mRNA-5671 / Moderna Therapeutics | - NSCLC - Colorectal cancer - Pancreatic adenocarcinoma |
mRNA-LNP | KRAS mutations - G12D - G12V - G13D - G12C |
Pembrolizumab | NCT03948763 / 1 |
C: Cysteine; D: Aspartate; G: Glycine; HPV-HNSCC: Human papillomavirus-negative head and neck squamous cell carcinoma; ICI: Immune checkpoint inhibitor; MAGE-3: Melanoma-associated antigen A3; MERIT: Mutanome Engineered RNA Immuno-Therapy; N.A.: Not applicable; NSCLC: Non-small cell lung cancer; NY-ESO-1: NewYork esophageal squamous cell carcinoma; OX40L: Ligand of OX40; TAA: Tumor associated antigen; TNBC: Triple negative breast cancer; TPTE: Transmembrane phosphatase with tensin homology; V: Valine.